SEHK:3933Pharmaceuticals
Assessing United Laboratories International Holdings (SEHK:3933) Valuation After UBT251 Clinical Trial Approval
United Laboratories International Holdings (SEHK:3933) has attracted fresh attention after China’s National Medical Products Administration approved clinical trials for UBT251 Injection, a self developed multi target peptide agonist for obstructive sleep apnea with obesity.
See our latest analysis for United Laboratories International Holdings.
That approval has arrived at a time when the stock’s short term momentum is picking up, with a 7 day share price return of 10.46% and a year to date...